Item 7.01 Regulation FD Disclosure.

On October 26, 2020, BioCardia, Inc. (the "Company") issued a press release announcing the publication of peer-reviewed initial data from the Company's initial open-label roll-in cohort that served as the precursor for the Company's ongoing CardiAMP HF Phase 3 clinical trial in the International Journal of Cardiology. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits

Exhibit No.    Exhibit Description
    99.1         Press Release of BioCardia, Inc. dated October 26, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses